ARTICLE | Clinical News
LT-02: Phase III started
November 17, 2014 8:00 AM UTC
Dr. Falk began the double-blind, placebo-controlled, German Phase III PROTECT-1 trial to evaluate 0.8 g LT-02 given 4 times daily and 1.6 g LT-02 twice daily in 762 adults with mesalazine-refractory U...